iBio Highlights Data from a Non-human Primate Study Supporting IBIO-610’s Potential to Preserve Muscle in Combination with GLP-1 Therapy
A projected human half-life could potentially support twice-yearly dosing of IBIO-610.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
iBio (IBIO) highlighted preclinical data showing a lower lean-mass share of weight loss when IBIO-610 was combined with semaglutide.
In an eight-week obese non-human primate study with six animals per group, lean mass accounted for 6% of weight lost with the combination, versus 22% with semaglutide alone. At week 8, fat accounted for 93% of weight lost with a single IBIO-610 dose alongside twice-weekly semaglutide, compared with 77% for semaglutide alone. Previously reported results showed a 97% reduction in serum levels of active Activin E, the antibody's target, at week 8 following one intravenous dose. iBio expects to begin first-in-human trials in the first half of 2027. The data were discussed at the EASD Annual Meeting on October 1, 2026.
How this balance works
Rhea-AI gives every point it takes from this document a weight. Minor counts 1, Moderate 3 and Major 9, so one Major point outweighs several Minor ones. The bar adds up the weights on each side, and when neither side holds more than 65% of the total the balance reads Mixed.
It reads the document as published, with the same rules for every company, and it does not look at what the market expected or at how the stock traded, so a point can be objectively good on a day the stock falls.
Rhea-AI Sentiment measures something else, the tone of the wording.
Hollow bars mark forward-looking points. How the balance works
Positive
- Moderate point. Forward-looking: it has not happened yet and may not happen.iBio expects to start first-in-human IBIO-610 trials in the first half of 2027.
- Minor pointCombination treatment's lean-mass share of weight loss was 6% versus 22% with semaglutide alone over eight weeks.
- Minor pointCombination treatment's fat share of weight loss was 93% versus 77% with semaglutide alone at week 8.
- Minor pointActive Activin E serum levels fell 97% at week 8 after a single intravenous IBIO-610 dose.
- Minor point. Forward-looking: it has not happened yet and may not happen.IBIO-610's 33.2-day half-life in non-human primates accompanied a projected human half-life potentially supporting twice-yearly dosing.
Negative
- Minor pointBody-composition results came from a study with only six non-human primates per group over eight weeks.
Details
Market Reaction – IBIO
On Oct 13, the day this news came out, the latest delayed price for IBIO is 7.10% below the previous close. Our momentum scanner has recorded 19 alerts for this stock so far that day. The latest delayed price is $0.84. Relative volume is elevated at 2.3x the average.
Data tracked by StockTitan Argus (15 min delayed). Upgrade to Gold for real-time data.
Key Figures
- Lean mass share of weight lost
- 6% with IBIO-610 plus semaglutide vs 22% with semaglutide alone
- Eight-week obese NHP study
- Fat share of weight lost
- 93% with IBIO-610 plus semaglutide vs 77% with semaglutide alone
- Week 8; IBIO-610 given as a single dose
- Active Activin E reduction
- 97%
- Week 8 after a single intravenous dose
- Study group size
- 6 NHPs per group
- Eight-week obese NHP study
- NHP half-life
- 33.2 days
- IBIO-610; human half-life projection may support twice-yearly dosing
- First-in-human trial timing
- First half of 2027
- Planned start for IBIO-610 studies
Historical Context
-
Earlier report documented 97% active Activin E reduction and 73% lower lean-mass loss with semaglutide.
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Key Terms
glp-1 receptor agonist medical
half-life medical
AI-generated analysis. How Rhea-AI works. Not financial advice.
In an eight-week obese NHP study, lean mass made up
iBio expects to start first-in-human trials of IBIO-610 in first half of 2027
SAN DIEGO, Oct. 13, 2026 (GLOBE NEWSWIRE) -- iBio, Inc. (NASDAQ: IBIO), a clinical-stage biotechnology company developing long-acting antibody therapeutics for obesity, cardiometabolic and cardiopulmonary diseases, highlighted preclinical body-composition data from its obese non-human primate (NHP) study evaluating IBIO-610, potentially a first-in-class Activin E antibody candidate, alone and in combination with semaglutide, a GLP-1 receptor agonist used to treat obesity. The data were discussed in an oral presentation at the European Association for the Study of Diabetes (EASD) Annual Meeting on October 1, 2026.
“While GLP-1 therapies have transformed obesity care, patients still need additional options to improve the quality of weight loss,” said Martin Brenner, DVM, Ph.D., Chief Executive Officer and Chief Scientific Officer of iBio. “In this NHP study, IBIO-610 delivered durable, near-complete inhibition of active Activin E, and when combined with semaglutide, nearly all observed weight loss came from fat. We plan to begin first-in-human studies in the first half of 2027. Our focus is on translating this biology into a potential new therapeutic option for patients living with obesity and cardiometabolic disease.”
Additional analysis of the eight-week obese NHP study (n=6 per group) further characterized the potential for IBIO-610 to support muscle preservation when combined with semaglutide. At week 8, fat accounted for
These results build on previously reported data from this NHP study, in which IBIO-610 demonstrated a
About iBio, Inc.
iBio (Nasdaq: IBIO) is a clinical-stage biotechnology developing long-acting antibody therapeutics for obesity, cardiometabolic and cardiopulmonary diseases, cancer, and other hard-to-treat diseases. Combining advanced antibody engineering with AI-driven discovery, iBio is advancing a differentiated pipeline designed to deliver sustained therapeutic effects and address significant unmet medical needs. iBio’s mission is to transform drug discovery, accelerate development timelines, and unlock new possibilities in precision medicine.
For more information, visit www.ibioinc.com or follow us on LinkedIn.
Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the federal securities laws, including statements about IBIO-610’s potential to preserve muscle in combination with semaglutide, a GLP-1 receptor agonist used to treat obesity; IBIO starting first-in-human trials of IBIO-610 in the first half of 2027; translating the biology into a potential new therapeutic option for patients living with obesity and cardiometabolic disease; IBIO-610 having a projected human half-life potentially supporting twice-yearly dosing; and iBio’s transforming drug discovery, accelerate development timelines, and unlock new possibilities in precision medicine. These statements reflect iBio’s current expectations and assumptions and are subject to risks and uncertainties that could cause actual results to differ materially, including the possibility that findings in NHPs will not be replicated in humans; IBIO’s ability to start first-in-human trials of IBIO-610 in the first half of 2027, risks of product development and regulatory approval, and the other risks described in iBio’s filings with the Securities and Exchange Commission, including its Annual Report on Form 10-K for the year ended June 30, 2026. Forward-looking statements speak only as of the date of this release. iBio undertakes no obligation to update them except as required by law.
Investor Contact
Matt Beck
astr partners
matthew.beck@astrpartners.com
(917) 415-1750
Media Contact
Jason Braco, Ph.D.
Valence Communications
jason@valencecomms.com
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What did iBio's IBIO-610 study show about lean mass during weight loss?
Lean mass accounted for 6% of weight lost with IBIO-610 plus semaglutide, versus 22% with semaglutide alone in an eight-week obese non-human primate study. Each group contained six animals. At week 8, fat accounted for 93% and 77% of weight lost, respectively.
When does iBio expect to begin human trials of IBIO-610?
iBio expects to begin first-in-human trials of IBIO-610 in the first half of 2027.
What dosing frequency could IBIO-610's half-life support?
IBIO-610's projected human half-life could potentially support twice-yearly dosing. Its measured half-life in non-human primates was 33.2 days; twice-yearly human dosing remains a potential schedule rather than an established result.